Metformin may prevent ER+ breast cancer
Use of metformin in patients with type 2 diabetes (T2D) appears to reduce their risk of developing oestrogen receptor (ER)-positive breast cancer, especially with long-term use, although there is no change in overall breast cancer risk — suggesting that the protective benefit of metformin may vary by hormone receptor status, according to the Sister Study.
